New drug combo before surgery may cut liver cancer recurrence
NCT ID NCT07518706
First seen Apr 24, 2026 · Last updated Apr 29, 2026 · Updated 1 time
Summary
This study tests whether giving two drugs (tislelizumab and lenvatinib) before surgery can lower the chance of liver cancer coming back in people with early-stage disease. About 60 adults with stage IA liver cancer and a narrow surgical margin will be randomly assigned to receive the drug combo then surgery, or surgery alone. The main goal is to see if the combo improves one-year survival without cancer returning.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HCC - HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.